Introduction: Lung cancer is one of the leading causes of cancer mortality worldwide. Although advances in treatment are significant, survival rates remain low, especially in advanced stages. Observational studies allow us to understand how the disease behaves in real clinical settings, helping to formulate public policies and therapeutic improvements. Objectives: Analyze clinical and epidemiological data of patients with lung cancer treated at a hospital institution, observing demographic characteristics, histological types, treatments, risk factors and clinical outcomes. Methods: Retrospective observational study carried out between 2018 and 2022, with 356 patients diagnosed with lung cancer. Variables such as age, sex, smoking, histological type, staging, treatment and survival were analyzed. CAAE: 84606024.9.0000.5173, Opinion Number: 7.331.126. Results: The results demonstrate the clinical and epidemiological profile of lung cancer patients, highlighting characteristics that are relevant to understanding the disease in real-world contexts. The men predominate (62%), most of whom are smokers (81%), reinforcing the strong link between smoking and the development of lung cancer, especially non-small cell lung cancer (NSCLC), which accounted for 78% of cases — with adenocarcinoma being the most common subtype (61%). The fact that more than half of the diagnoses occurred at stage IV (54%) points to a pattern of late detection, which limits therapeutic options and reduces survival. In terms of treatment, most patients underwent chemotherapy and/or radiotherapy (65%), with smaller proportions receiving immunotherapy (28), surgery (22%) or targeted therapy (12%). These data reflect both the severity of the cases and possible barriers to access to more advanced technologies, especially in the public health system, where inequality in access to modern therapies stands out as a limiting factor. The median survival of 14.8 months, with better outcomes (up to 30 months) in patients with early-stage NSCLC, reinforces the importance of early diagnosis and timely access to effective treatments. Conclusion: This observational study reinforces the importance of early diagnosis and access to modern therapies in the treatment of lung cancer. Despite advances, most cases are still diagnosed late, especially among smokers. There is an urgent need to expand access to molecular tests and personalized treatments, in addition to strengthening prevention and screening programs for the disease.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
